Drug firm sees newbuilds as prescription for success
SHIPBUILDING has become so lucrative that a pharmaceutical firm in China is taking $19.8m punt on the newbuildings market, writes Sandra Tsui in Hong Kong.
If content does not display, please refresh your browser.
Not a subscriber?
Find out about tailored subscription packages:
T: +44 (0) 20 3377 3792